JP2010519221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519221A5 JP2010519221A5 JP2009550145A JP2009550145A JP2010519221A5 JP 2010519221 A5 JP2010519221 A5 JP 2010519221A5 JP 2009550145 A JP2009550145 A JP 2009550145A JP 2009550145 A JP2009550145 A JP 2009550145A JP 2010519221 A5 JP2010519221 A5 JP 2010519221A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- leukemia
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- 125000003118 aryl group Chemical group 0.000 claims 15
- 239000002246 antineoplastic agent Substances 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 239000003112 inhibitor Substances 0.000 claims 12
- -1 -S (O) n R 4 Chemical group 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 10
- 208000032839 leukemia Diseases 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 230000019491 signal transduction Effects 0.000 claims 7
- 208000011580 syndromic disease Diseases 0.000 claims 7
- 102100027188 Thyroid peroxidase Human genes 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 239000000018 receptor agonist Substances 0.000 claims 6
- 229940044601 receptor agonist Drugs 0.000 claims 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 5
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 4
- 206010057644 Testis cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 4
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 201000003120 testicular cancer Diseases 0.000 claims 4
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 3
- 229940121742 Serine/threonine kinase inhibitor Drugs 0.000 claims 3
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 3
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 230000022131 cell cycle Effects 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- OFZJKCQENFPZBH-UHFFFAOYSA-N 1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=NC=C(C(=O)NC=2SC(=C(C=3SC=C(Cl)C=3)N=2)N2CCN(CC2)C2CCCCC2)C=C1Cl OFZJKCQENFPZBH-UHFFFAOYSA-N 0.000 claims 2
- FJGSNTBRCKGXLV-UHFFFAOYSA-N 3-[3-[2-[1-(3,5-dimethylphenyl)-2-oxo-6-(trifluoromethyl)indol-3-ylidene]hydrazinyl]-2-hydroxyphenyl]benzoic acid Chemical compound CC1=CC(C)=CC(N2C3=CC(=CC=C3C(=NNC=3C(=C(C=4C=C(C=CC=4)C(O)=O)C=CC=3)O)C2=O)C(F)(F)F)=C1 FJGSNTBRCKGXLV-UHFFFAOYSA-N 0.000 claims 2
- CVHQVUURUVOXGY-UHFFFAOYSA-N 4-[2-hydroxy-3-[2-[2-oxo-1-(4-propylphenyl)indol-3-ylidene]hydrazinyl]phenyl]benzoic acid Chemical compound C1=CC(CCC)=CC=C1N(C1=O)C2=CC=CC=C2C1=NNC1=CC=CC(C=2C=CC(=CC=2)C(O)=O)=C1O CVHQVUURUVOXGY-UHFFFAOYSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 239000005973 Carvone Substances 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 2
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 2
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims 2
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 claims 2
- 206010027145 Melanocytic naevus Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000007256 Nevus Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000000389 T-cell leukemia Diseases 0.000 claims 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 241000863480 Vinca Species 0.000 claims 2
- 206010047741 Vulval cancer Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 229940044684 anti-microtubule agent Drugs 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 150000004141 diterpene derivatives Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims 2
- 210000000981 epithelium Anatomy 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000008026 nephroblastoma Diseases 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 208000014081 polyp of colon Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
- 229960002066 vinorelbine Drugs 0.000 claims 2
- 201000005102 vulva cancer Diseases 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 claims 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 101150111783 NTRK1 gene Proteins 0.000 claims 1
- 101150117329 NTRK3 gene Proteins 0.000 claims 1
- 101150056950 Ntrk2 gene Proteins 0.000 claims 1
- 229940123282 Oncogene inhibitor Drugs 0.000 claims 1
- 102000038030 PI3Ks Human genes 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 102000001332 SRC Human genes 0.000 claims 1
- 108060006706 SRC Proteins 0.000 claims 1
- 229940122924 Src inhibitor Drugs 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003668 hormone analog Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 claims 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 108700042226 ras Genes Proteins 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 102000009076 src-Family Kinases Human genes 0.000 claims 1
- 108010087686 src-Family Kinases Proteins 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003558 transferase inhibitor Substances 0.000 claims 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89023607P | 2007-02-16 | 2007-02-16 | |
| US60/890,236 | 2007-02-16 | ||
| US89255207P | 2007-03-02 | 2007-03-02 | |
| US60/892,552 | 2007-03-02 | ||
| US90820507P | 2007-03-27 | 2007-03-27 | |
| US60/908,205 | 2007-03-27 | ||
| US94934707P | 2007-07-12 | 2007-07-12 | |
| US60/949,347 | 2007-07-12 | ||
| US95228907P | 2007-07-27 | 2007-07-27 | |
| US60/952,289 | 2007-07-27 | ||
| US96919207P | 2007-08-31 | 2007-08-31 | |
| US60/969,192 | 2007-08-31 | ||
| US97721607P | 2007-10-03 | 2007-10-03 | |
| US60/977,216 | 2007-10-03 | ||
| PCT/US2008/054046 WO2008101141A2 (en) | 2007-02-16 | 2008-02-15 | Cancer treatment method |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010519221A JP2010519221A (ja) | 2010-06-03 |
| JP2010519221A5 true JP2010519221A5 (enExample) | 2011-04-07 |
| JP5511391B2 JP5511391B2 (ja) | 2014-06-04 |
Family
ID=39690807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009550145A Active JP5511391B2 (ja) | 2007-02-16 | 2008-02-15 | 癌の治療方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20100075928A1 (enExample) |
| EP (1) | EP2124547B3 (enExample) |
| JP (1) | JP5511391B2 (enExample) |
| KR (1) | KR101447763B1 (enExample) |
| CN (1) | CN101662937B (enExample) |
| AR (1) | AR065348A1 (enExample) |
| AU (1) | AU2008216106C1 (enExample) |
| BR (1) | BRPI0807940B8 (enExample) |
| CA (1) | CA2678358C (enExample) |
| CR (1) | CR10997A (enExample) |
| DK (1) | DK2124547T6 (enExample) |
| EA (1) | EA017715B1 (enExample) |
| ES (1) | ES2675070T7 (enExample) |
| FI (1) | FI2124547T4 (enExample) |
| HU (1) | HUE038563T2 (enExample) |
| IL (2) | IL200319A (enExample) |
| MA (1) | MA31202B1 (enExample) |
| MX (1) | MX2009008822A (enExample) |
| NZ (1) | NZ579068A (enExample) |
| PE (1) | PE20081784A1 (enExample) |
| PL (1) | PL2124547T5 (enExample) |
| PT (1) | PT2124547T (enExample) |
| SI (1) | SI2124547T2 (enExample) |
| TR (1) | TR201809010T4 (enExample) |
| TW (1) | TW200906393A (enExample) |
| UY (1) | UY30915A1 (enExample) |
| WO (1) | WO2008101141A2 (enExample) |
| ZA (1) | ZA200905532B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110160130A1 (en) * | 2007-02-16 | 2011-06-30 | Connie Erickson-Miller | Cancer treatment method |
| US20110129550A1 (en) * | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
| ECSP077628A (es) | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | Nueva composición farmacéutica |
| CN101888841B (zh) * | 2007-10-09 | 2012-09-26 | 宾夕法尼亚大学理事会 | 血小板生成素受体激动剂(TpoRA)杀死急性人骨髓样白血病细胞 |
| CA2763768A1 (en) | 2009-05-29 | 2010-12-02 | Glaxosmithkline Llc | Methods of administration of thrombopoietin agonist compounds |
| JP2013538810A (ja) * | 2010-09-01 | 2013-10-17 | ノバルティス アーゲー | Ｈｄａｃ阻害剤と血小板減少症薬との組合せ |
| US9962370B2 (en) | 2013-03-15 | 2018-05-08 | Ligand Pharmaceuticals Incorporated | Methods of treatment associated with the granulocyte colony-stimulating factor receptor |
| SG10201913416PA (en) * | 2016-05-06 | 2020-03-30 | Taris Biomedical Llc | Method of treating lower tract urothelial cancer |
| RU2675695C1 (ru) * | 2018-03-06 | 2018-12-24 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации | Способ лечения рака предстательной железы высокого и очень высокого риска |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| US5342947A (en) * | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| AP9300587A0 (en) * | 1992-11-12 | 1995-05-05 | Glaxo Inc | Water soluble camptothecin derivatives. |
| US5681835A (en) * | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5491237A (en) * | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
| US6316652B1 (en) * | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| WO1999011262A1 (en) | 1997-09-02 | 1999-03-11 | Roche Diagnostics Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia |
| US7026334B1 (en) * | 1999-07-26 | 2006-04-11 | Shionogi & Co., Ltd. | Thiazolidine compounds and pharmaceutical compositions exhibiting thrombopoietin receptor agonism |
| EP2087907B1 (en) * | 1999-11-10 | 2014-09-24 | Innatus Corporation | Method and system to remove cytokine inhibitor in patients |
| EP1104674A1 (de) | 1999-11-10 | 2001-06-06 | Curacyte AG | O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| CY2010012I2 (el) * | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| JP3966816B2 (ja) * | 2000-05-30 | 2007-08-29 | 中外製薬株式会社 | トロンボポエチン様活性を有する化合物 |
| EP1284997B1 (en) * | 2000-05-31 | 2005-04-06 | Genzyme Corporation | Therapeutic compounds for ovarian cancer |
| DE60203260T2 (de) * | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
| CA2435143A1 (en) | 2001-01-26 | 2002-08-01 | Shionogi & Co., Ltd. | Halogen compounds having thrombopoietin receptor agonism |
| US7169931B2 (en) | 2001-01-26 | 2007-01-30 | Shionogi & Co., Ltd. | Cyclic compounds exhibiting thrombopoietin receptor agonism |
| WO2002062775A1 (en) | 2001-02-02 | 2002-08-15 | Yamanouchi Pharmaceutical Co., Ltd. | 2-acylaminothiazole derivative or its salt |
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| PL370867A1 (en) * | 2001-09-24 | 2005-05-30 | Tosk, Inc. | Reduced toxicity cisplatin formulations and methods for using the same |
| ES2610611T3 (es) * | 2002-01-18 | 2017-04-28 | Astellas Pharma Inc. | Derivado de 2-acilaminotiazol o sal del mismo |
| AR040083A1 (es) * | 2002-05-22 | 2005-03-16 | Smithkline Beecham Corp | Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac |
| WO2004029049A1 (ja) * | 2002-09-30 | 2004-04-08 | Yamanouchi Pharmaceutical Co., Ltd. | 2-アシルアミノチアゾール誘導体の新規な塩 |
| WO2004096154A2 (en) | 2003-04-29 | 2004-11-11 | Smithkline Beecham Corporation | Methods for treating degenerative diseases/injuries |
| WO2005118551A2 (en) * | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
| CA2583764C (en) * | 2004-10-25 | 2009-06-09 | Ligand Pharmaceuticals, Inc. | Thrombopoietin activity modulating compounds and methods |
| BRPI0620532A2 (pt) | 2005-11-23 | 2011-11-16 | Ligand Pharm Inc | compostos e métodos para modular a atividade de trombopoietina |
| US20100063301A1 (en) | 2006-03-15 | 2010-03-11 | Ligand Pharmaceuticals Inc | Synthesis of thrombopoietin activity modulating compounds |
-
2008
- 2008-02-13 UY UY30915A patent/UY30915A1/es unknown
- 2008-02-14 AR ARP080100631A patent/AR065348A1/es not_active Application Discontinuation
- 2008-02-14 TW TW097105201A patent/TW200906393A/zh unknown
- 2008-02-14 PE PE2008000322A patent/PE20081784A1/es not_active Application Discontinuation
- 2008-02-15 PL PL08729939.2T patent/PL2124547T5/pl unknown
- 2008-02-15 NZ NZ579068A patent/NZ579068A/en not_active IP Right Cessation
- 2008-02-15 HU HUE08729939A patent/HUE038563T2/hu unknown
- 2008-02-15 KR KR1020097019224A patent/KR101447763B1/ko active Active
- 2008-02-15 PT PT87299392T patent/PT2124547T/pt unknown
- 2008-02-15 ES ES08729939T patent/ES2675070T7/es active Active
- 2008-02-15 MX MX2009008822A patent/MX2009008822A/es active IP Right Grant
- 2008-02-15 TR TR2018/09010T patent/TR201809010T4/tr unknown
- 2008-02-15 BR BRPI0807940A patent/BRPI0807940B8/pt active IP Right Grant
- 2008-02-15 US US12/527,220 patent/US20100075928A1/en not_active Abandoned
- 2008-02-15 EA EA200970776A patent/EA017715B1/ru not_active IP Right Cessation
- 2008-02-15 SI SI200831968T patent/SI2124547T2/sl unknown
- 2008-02-15 CN CN200880012425.7A patent/CN101662937B/zh active Active
- 2008-02-15 DK DK08729939.2T patent/DK2124547T6/da active
- 2008-02-15 EP EP08729939.2A patent/EP2124547B3/en active Active
- 2008-02-15 WO PCT/US2008/054046 patent/WO2008101141A2/en not_active Ceased
- 2008-02-15 JP JP2009550145A patent/JP5511391B2/ja active Active
- 2008-02-15 AU AU2008216106A patent/AU2008216106C1/en active Active
- 2008-02-15 FI FIEP08729939.2T patent/FI2124547T4/fi active
- 2008-02-15 CA CA2678358A patent/CA2678358C/en active Active
- 2008-07-02 US US12/166,686 patent/US20090022814A1/en not_active Abandoned
-
2009
- 2009-08-07 ZA ZA200905532A patent/ZA200905532B/xx unknown
- 2009-08-10 IL IL200319A patent/IL200319A/en active IP Right Grant
- 2009-08-26 CR CR10997A patent/CR10997A/es not_active Application Discontinuation
- 2009-08-31 MA MA32188A patent/MA31202B1/fr unknown
-
2015
- 2015-04-20 IL IL238394A patent/IL238394B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010519221A5 (enExample) | ||
| CN115768427B (zh) | 癌症疗法中用于靶向降解不可靶向的kras的新型小分子 | |
| Lotfy et al. | Synthesis of new spirooxindole-pyrrolothiazole derivatives: Anti-cancer activity and molecular docking | |
| JP5323289B1 (ja) | 新規ピペリジン化合物又はその塩 | |
| JP2020007311A5 (enExample) | ||
| CN110772639A (zh) | Bcl-2抑制剂与MDM2抑制剂的组合产品及其在预防和/或治疗疾病中的用途 | |
| CN105358156A (zh) | 双重mek/pi3k抑制剂和使用其的治疗方法 | |
| AU2008216106C1 (en) | Cancer treatment method | |
| Avdieiev et al. | Bradykinin antagonists and thiazolidinone derivatives as new potential anti-cancer compounds | |
| CN106456616A (zh) | 小分子C‑Myc抑制剂 | |
| Zhu et al. | Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy | |
| ES2440799T3 (es) | Métodos para tratar cáncer resistente a los fármacos | |
| KR20110056325A (ko) | Ｎ-［6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일］-2-메틸-4'-(트리플루오로메톡시)［1,1'-비페닐］-3-카르복스아미드의 염 | |
| JP2023531228A (ja) | ピリミジン誘導体及びその製造方法並びにその使用 | |
| JP6445082B2 (ja) | ５’−ヒドロキシ−５−ニトロ−インジルビン−３’−オキシムを有効成分として含有する乳がん治療剤 | |
| KR20210116325A (ko) | 티아졸 유도체 또는 이의 약제학적으로 허용가능한 염을 포함하는 암의 예방 또는 치료용 약학 조성물 | |
| WO2012119506A1 (zh) | 吲哚酮类衍生物、其药物组合物、其制备方法和用途 | |
| CN114853746A (zh) | 甲酰胺类化合物、其制备方法及其在医药上的应用 | |
| JP2018527321A (ja) | クロロベンゼン置換されたアザアリール化合物 | |
| TWI916370B (zh) | 用於在癌症治療中對不可標定之kras進行降解標定之新穎小分子 | |
| JP2019517572A (ja) | がんにおけるシグマ受容体リガンドの使用 | |
| Xiao | Discovery of Novel Tubulin Polymerization Inhibitors and Survivin Inhibitors as Potential Anticancer Agents | |
| Mallikarjuna Rao et al. | Design and Synthesis of Some Isatin-Thiazolidine-2, 4-Dione-Pyrazoles as VEGFR-2 Targeting Anti-Proliferative Agents | |
| BR112017018858B1 (pt) | 4-amino-3-fenilamino-6-fenilpirazol[3,4-d]pirimidina, e, uso de uma composição farmacêutica o compreendendo | |
| HK1199730B (en) | Piperidine compound or salt thereof |